Loading organizations...
§ Private Profile · Suzhou, Jiangsu, China
Tissue engineering platform developing blood vessels and tissues for regenerative medicine and cardiovascular applications.
Haimai Medical develops a tissue engineering platform for regenerative medicine, focusing on creating blood vessels and other tissues to advance treatments. This innovative technology aims to enable regenerative solutions for a broad spectrum of medical applications, with a particular emphasis on cardiovascular health. The company's research and development efforts are directed towards engineering functional tissues that can address significant unmet needs in areas requiring biological repair or replacement. By leveraging advanced principles from both biological sciences and material engineering, Haimai Medical seeks to mimic the intricate structures and functions of natural human tissues. Their platform is designed to facilitate the creation of novel therapeutic interventions, potentially offering improved long-term outcomes for patients suffering from complex conditions that currently lack effective regenerative options. This foundational work is positioned to contribute to the evolution of regenerative medicine by providing scalable and biologically compatible tissue solutions.
Haimai Medical has raised $14.3M across 1 funding round.
Haimai Medical has raised $14.3M in total across 1 funding round.
Haimai Medical has raised $14.3M across 1 funding round. Most recently, it raised $14.3M Series A in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 30, 2025 | $14.3M Series A | — | IDG Capital, Shanghai Healthcare Capital | Announced |
Haimai Medical has raised $14.3M in total across 1 funding round.
Haimai Medical's investors include IDG Capital, Shanghai Healthcare Capital.